RBC Capital Markets | Pathfinders in Biopharma

Featured Biopharma Content

Insights

The Optimism Behind the Biopharma Market

In this episode, Dr. Chen Yu, Founder and Managing Partner at TCG X and Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, discuss why they remain optimistic about biotech and what’s happening behind the scenes in public and private markets.

Listen Now Read Article

Listen Time 25m 5m

Insights

Biopharma Looks Increasingly Attractive to Investors

In a volatile market, biotech is still an underappreciated prospect, with high innovation and defensiveness to attract investors and key upcoming events that could solidify sentiment.

Read Article

5m

Research

Pandemic Produced Lasting Changes in Medical Device Markets

Following RBC’s Global Healthcare Conference, BioWorld MedTech published an article about the top trends discussed that will continue to reshape healthcare and medtech.

Read Article

3m

Research | Healthcare

Outlook for Healthcare Services, IT and Devices Remains Strong

Despite macroeconomic challenges, healthcare remains a strong sector for investment. Labor headwinds and inflation may temper growth in the short term, but medium- and long-term outlooks and fundamentals remain intact.

Read Article

4m

Sector Spotlight | Healthcare

“Large pharma has $500B it could deploy for M&A.”

What are the challenges and opportunities for the healthcare sector post-pandemic? Where might we see innovations that drive M&A growth?

Watch Video Read Article

4m 3m

Pathfinders Podcast | Global Markets

Biotech Investors: How to Find Value in a Bear Market

How are top investors navigating the longest biotech bear market in almost 20 years?

Listen Now Read Article

Listen Time 29m 5m

Research

Biotech Outlook 2022: Ample Opportunity for a Rebound

After an historic run in 2020, the biotech sector had a difficult year with slower activity in 2021. The pendulum, however, may be ready to swing back the other way.

Read Article

4m

Research

Digital Health Outlook 2022: Opportunities for the Discerning Investor

The digital health market was challenging in 2021, despite the broader macro demand remaining very healthy. While the long term opportunity is clear, the sector is maturing and evolving, which makes it more difficult to pinpoint which strategies or vendors will prevail.

Read Article

3m

Research

Healthcare Experts See Near-term Hurdles, but Long-term Optimism in the Sector

Recovery from the knock-on effects of the pandemic, like patient backlogs and staffing shortages, won’t happen quickly but innovation in therapies and technologies continue to power the sector forward.

Read Article

5m

Pathfinders Podcast | Research

Global Blood Therapeutics on tackling orphan disease

What does it take to tackle the most perplexing orphan diseases? Ted W. Love, M.D., President and CEO, Global Blood Therapeutics (GBT), speaks with RBC Capital Markets’ Senior Biotechnology Analyst Gregory Renza, M.D. about having a mission and the drive to succeed on this episode of Pathfinders.

Listen Now Read Article

Listen Time 27m 3m

Insights

Biotechs Race for Next-Gen Dystrophy and Ataxia Treatments

Discover how biotechs are harnessing next-generation techniques to find treatments for people with rare movement and neuromuscular disorders.

Read Article

3m

Pathfinders Podcast | Research

Ionis: Raising the Bar for ESG

In this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Beth Hougen, CFO of Ionis Pharma – a leading innovator in the development of antisense medicines and RNA-targeted therapeutics – to find out how the firm is embedding ESG into its vision, strategy and performance.

Listen Now Read Article

Listen Time 24m 3m

Pathfinders Podcast | Investment Banking

Biotech and Big Pharma: Blueprint for Successful Partnership

As biotech firms and large pharma companies find new synergies to bring new treatments to market together, RBC Capital Markets’ Noël Brown interviews pharma industry veteran Greg Wiederrecht – now RBC’s Biopharma Managing Director - on what it takes to ensure a strategic partnership not only survives but thrives.

Listen Now Read Article

Listen Time 23m 5m

Research

Biotech Halftime Report: After a Bumpy Year, is Biotech Ready to Bounce Back?

There are encouraging signs that biotech is approaching a bottom after a rough start to 2021, but it’s difficult to call when the sector will bounce back.

Read Article

4m

Research

Game Changers: Disruptive Forces in Biotech

The biopharma sector continues to disrupt and be disrupted. Whether it’s products and technologies, legal developments or the knock-on effects of the coronavirus pandemic, there is a quiet revolution taking place right now that holds the potential to radically transform the world of healthcare. The paradigm shift in how we care for ourselves is already underway.

Read Article

4m

Pathfinders Podcast | Investment Banking

Inside Track: Behind the Scenes of a Major Biotech SPAC

RBC Capital Markets’ Noël Brown, Head of US Biotech Investment Banking, goes behind the scenes of one of the biggest biotech SPAC deals of the year with Nuvation Bio Founder and CEO, Dr. David Hung and Omega Funds Partner and President of its Omega Alpha SPAC, Michelle Doig.

Listen Now Read Article

Listen Time 24m 4m

Research

All eyes on gene/cell therapy and rare disease innovations

Every spring, RBC Capital Markets brings together key opinion leaders across major therapeutic areas in biotech for a series of Doctor Day sessions. This year, RBC’s Biotech Equity Research Analysts hosted experts with medical specialties from rare diseases to oncology to talk about future treatments, exciting innovations and life-changing advances. Many of these health issues have little in common, but there’s one area of innovation that could help treat them all – gene and cell therapies.

Read Article

5m

Research

Genetic Medicine Leads a Surge of Innovation in Biotech

According to RBC’s Senior Biotech Equity Analyst, Luca Issi, genetic medicine (the delivery of genetic material as a therapeutic) has attracted record-breaking capital in Biotech with ~$150b deployed across venture, IPOs, follow-ons and M&A since 2013. For context, that compares to the GDP of a top 50-60 country worldwide.

Read Article

3m

Pathfinders Podcast | Research

What’s Material in ESG for Biopharma Firms?

In this episode of Pathfinders, Brian Abrahams, Co-Head of Biotechnology Equity Research at RBC Capital Markets speaks with the team of ESG leads at Gilead Sciences to understand the five key components driving the company’s ESG strategy, how this strategy has evolved and how it drives business impact.

Listen Now Read Article

Listen Time 18m 4m

Research

How the FDA’s Approval Of A New Alzheimer’s Drug Could Ripple Across the Biopharma Sector

In potentially the largest biotech event of this year, the FDA has approved Biogen’s aducanumab, an Alzheimer’s drug. RBC Capital Markets’ equity research analysts outline how this much-anticipated decision may have far-reaching effects for the industry.

Read Article

2m

Research

#RBCHealthcare2021: Key Takeaways from our Global Healthcare Conference

At RBC Capital Markets’ virtual Global Healthcare Conference, experts, top firms and former government officials gathered virtually to discuss a dynamic biopharma market, the rise of SPACs as a vehicle for going public, and the future of the US healthcare system.

Read Article

3m